US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

25.01

-3.9700-13.70%

Post-market: 25.010.00000.00%16:48 EST

Volume:839.10K

Turnover:21.79M

Market Cap:1.35B

PE:-9.53

High:29.89

Open:29.61

Low:24.61

Close:28.98

52wk High:33.00

52wk Low:5.14

Shares:54.04M

Float Shares:31.42M

Volume Ratio:1.39

T/O Rate:2.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6241

EPS(LYR):-5.5835

ROE:-40.80%

ROA:-28.15%

PB:3.57

PE(LYR):-4.48

Loading ...

Overview Company News Filings

Upstream Bio Initiated at Outperform by LifeSci Capital

Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements

Upstream Bio Initiated at Outperform by Evercore ISI Group

Upstream Bio initiated with an Outperform at Evercore ISI

Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets

Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline

Upstream Bio Inc Files for Mixed Shelf ; Size Not Disclosed - SEC Filing

THOMSON REUTERS

Upstream Bio reports Q3 net loss of $33.7 million on higher R&D expenses

Upstream Bio (UPB): Evaluating Valuation After NORGES BANK’s Strategic Stake Boost

Simply Wall St.

Upstream Bio Inc. to Participate in Stifel Healthcare Conference

Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating

Upstream Bio (UPB) Is Up 15.4% After Analyst Upgrades on Verekitug Data Is Sentiment Justified?

Simply Wall St.

Upstream Bio, Inc. (UPB) Receives a Buy from Piper Sandler

Upstream Bio (UPB): Fresh Data and Analyst Coverage Spark New Questions on Valuation

Simply Wall St.

Upstream Bio Initiated at Buy by Truist Securities

Upstream Bio initiated with a Buy at Truist

Why Upstream Bio (UPB) Is Up 6.5% After Positive Phase 2 Results for Verekitug in Respiratory Diseases

Simply Wall St.

HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%

Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease

Upstream Bio Announces Promising Phase 2 Clinical Results for Verekitug in Severe Respiratory Diseases at ERS Congress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/UPB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":25.01,"timestamp":1764709200000,"preClose":28.98,"halted":0,"volume":839097,"hourTrading":{"tag":"盘后","latestPrice":25.01,"preClose":25.01,"latestTime":"16:48 EST","volume":1135,"amount":28386.350000000002,"timestamp":1764712127721},"delay":0,"floatShares":31417476,"shares":54038591,"eps":-2.624147,"marketStatus":"Post-Mkt","change":-3.97,"latestTime":"12-02 17:44:00 EST","open":29.61,"high":29.89,"low":24.61,"amount":21792632.069313,"amplitude":0.182195,"askPrice":37.44,"askSize":100,"bidPrice":20.58,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.624147,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":28.98,"preHourTrading":{"tag":"盘前","latestPrice":29.95,"preClose":28.98,"latestTime":"08:42 EST","volume":2942,"amount":86414.342184,"timestamp":1764682968901},"postHourTrading":{"tag":"盘后","latestPrice":25.01,"preClose":25.01,"latestTime":"16:48 EST","volume":1135,"amount":28386.350000000002,"timestamp":1764712127721},"volumeRatio":1.392511,"impliedVol":0.9574,"impliedVolPercentile":0.7315},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-28.15%","roe":"-40.80%","lyrEps":-5.58348,"volumeRatio":1.392511,"shares":54038591,"dividePrice":0,"high":29.89,"amplitude":0.182195,"preClose":28.98,"low":24.61,"week52Low":5.14,"pbRate":"3.57","psRate":"482.85","week52High":33,"institutionHeld":0,"latestPrice":25.01,"eps":-2.624147,"divideRate":0,"volume":839097,"delay":0,"ttmEps":-2.624147,"open":29.61,"prevYearClose":16.44,"prevWeekClose":28.6,"prevMonthClose":28.6,"prevQuarterClose":18.81,"fiveDayClose":26.05,"twentyDayClose":25.02,"sixtyDayClose":18.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1760590800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2025-12-01","current":-11.043589,"percent":0.242958,"low":-36.237602,"twenty":-16.389035,"median":-9.06956,"eighty":-7.396957,"high":-5.184222,"avg":-12.024248,"sd":7.244108,"marketCap":1545503702},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-01","current":-12.644639,"twenty":-16.389035,"median":-9.06956,"eighty":-7.396957,"marketCap":1545503702}],"updateTime":1764679843430},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588605370","title":"Upstream Bio Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588605370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588605370?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:04","pubTimestamp":1764680640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 08:04 ET (13:04 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2586542740","title":"Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2586542740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586542740?lang=en_us&edition=fundamental","pubTime":"2025-11-25 19:55","pubTimestamp":1764071749,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating on November 18. Tessa Romero’s rating is bas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-upstream-bio-inc-driven-by-verekitugs-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-upstream-bio-inc-driven-by-verekitugs-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261372.USD","LU0314104364.USD","BK4504","LU1162221912.USD","LU2271345857.HKD","LU0158827781.USD","LU0098860793.USD","LU1720051108.HKD","LU2357305700.SGD","BK4581","LU1791710400.SGD","LU1732800096.USD","BK4588","LU1074936037.SGD","LU1244550577.SGD","LU1244550221.USD","LU0971096721.USD","LU1989772840.SGD","LU1244550494.USD","LU0158827948.USD","LU2089283258.USD","LU0267386448.USD","UPB","BK4139","LU0528227936.USD","LU0795875086.SGD","LU2089284900.SGD","LU1791710582.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0106831901.USD","LU0557290698.USD","LU0006306889.USD","LU1720051017.SGD","LU1668664300.SGD","LU2111349929.HKD","LU1989772923.USD","LU2133065610.SGD","BK4127","LU2023251221.USD","BK4585","LU1363072403.SGD","LU0912757837.SGD","LU0795875169.SGD","LU0882574139.USD","LU1732799900.SGD","LU2347655156.SGD","IE00BZ1G4Q59.USD","BK4534","BK4516"],"gpt_icon":0},{"id":"2584370937","title":"Upstream Bio Initiated at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2584370937","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584370937?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:50","pubTimestamp":1763470200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 07:50 ET (12:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2584933652","title":"Upstream Bio initiated with an Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584933652?lang=en_us&edition=fundamental","pubTime":"2025-11-18 17:55","pubTimestamp":1763459715,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov initiated coverage of Upstream Bio (UPB) with an Outperform rating and $40 price target The firm says the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-an-outperform-at-evercore-isi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-an-outperform-at-evercore-isi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2584933569","title":"Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584933569?lang=en_us&edition=fundamental","pubTime":"2025-11-18 17:46","pubTimestamp":1763459190,"startTime":"0","endTime":"0","summary":"Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by Evercore ISI analyst, Cory Kasimov. Cory Kasimov has given his Buy rating due ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-s-verekitug-a-promising-buy-with-blockbuster-potential-in-asthma-and-copd-markets-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-s-verekitug-a-promising-buy-with-blockbuster-potential-in-asthma-and-copd-markets-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2581746637","title":"Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2581746637","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581746637?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:55","pubTimestamp":1762358152,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on October 20. Matt Phipps has given his Bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-receives-buy-rating-due-to-promising-clinical-trial-results-and-strong-drug-pipeline-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-receives-buy-rating-due-to-promising-clinical-trial-results-and-strong-drug-pipeline-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2581172250","title":"Upstream Bio Inc Files for Mixed Shelf ; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581172250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581172250?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:38","pubTimestamp":1762346286,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH0R3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2581729242","title":"Upstream Bio reports Q3 net loss of $33.7 million on higher R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2581729242","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581729242?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344048,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. reported a net loss of $33.7 million for the third quarter ended September 30, 2025, compared to a net loss of $16.0 million for the same period in 2024. Research and development expenses were $33.0 million, up from $15.4 million, primarily due to increased clinical and manufacturing expenses for the verekitug programs. General and administrative expenses rose to $5.5 million from $4.1 million, mainly driven by higher personnel-related and professional service fees. As of September 30, 2025, the company held $372.4 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027. Key business developments included positive top-line results from the Phase 2 VIBRANT trial of verekitug in CRSwNP, ongoing enrollment in the VENTURE Phase 2 trial in COPD, and plans to report top-line results from the VALIANT Phase 2 trial in severe asthma in the first quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1FN7TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4139","LU2210149790.SGD","BK4588","LU2210150020.SGD","UPB","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","BK4112"],"gpt_icon":0},{"id":"2580268902","title":"Upstream Bio (UPB): Evaluating Valuation After NORGES BANK’s Strategic Stake Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2580268902","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580268902?lang=en_us&edition=fundamental","pubTime":"2025-11-03 11:16","pubTimestamp":1762139804,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) caught investor attention after NORGES BANK acquired nearly 2 million shares, increasing its overall stake to just over 5%. The move suggests institutional interest in the company’s pipeline of therapies.\nSee our latest analysis for Upstream Bio.\nThe surge in Upstream Bio’s share price, up an impressive 38.8% over the last 30 days, mirrors renewed optimism after NORGES BANK’s stake increase and management’s high-profile conference appearances. While total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-evaluating-valuation-after-norges-banks-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-evaluating-valuation-after-norges-banks-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2579463895","title":"Upstream Bio Inc. to Participate in Stifel Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579463895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579463895?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908417,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc., a clinical-stage company focused on treatments for inflammatory diseases, will present at the Stifel 2025 Healthcare Conference in New York on November 11, 2025, at 9:20 a.m. ET. A live webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL4f5Cv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","LU2210150020.SGD","SF","BK4585","IE00BKPKM429.USD","UPB","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4127","BK4588","NDAQ"],"gpt_icon":0},{"id":"2579125026","title":"Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2579125026","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579125026?lang=en_us&edition=fundamental","pubTime":"2025-10-30 22:25","pubTimestamp":1761834335,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on October 20. Matt Phipps has given his Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bios-promising-trials-and-strategic-outlook-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bios-promising-trials-and-strategic-outlook-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2577938332","title":"Upstream Bio (UPB) Is Up 15.4% After Analyst Upgrades on Verekitug Data Is Sentiment Justified?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577938332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577938332?lang=en_us&edition=fundamental","pubTime":"2025-10-22 05:19","pubTimestamp":1761081591,"startTime":"0","endTime":"0","summary":"In recent days, several analyst firms reiterated positive ratings on Upstream Bio following promising Phase 2 trial results for its drug candidate verekitug.\nThis heightened attention underscores the potential for verekitug to stand out in the competitive respiratory biologics market, particularly with anticipation surrounding upcoming severe asthma trial outcomes.\nWe'll explore how investor optimism for verekitug's unique potential is shaping Upstream Bio's investment narrative.\nThe end of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-is-up-154-after-analyst-upgrades-on-verekit","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-is-up-154-after-analyst-upgrades-on-verekit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UPB"],"gpt_icon":0},{"id":"2576852697","title":"Upstream Bio, Inc. (UPB) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2576852697","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576852697?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:56","pubTimestamp":1760964991,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Upstream Bio, Inc., with a price target of $75.00. The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/upstream-bio-inc-upb-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/upstream-bio-inc-upb-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2576432023","title":"Upstream Bio (UPB): Fresh Data and Analyst Coverage Spark New Questions on Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2576432023","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576432023?lang=en_us&edition=fundamental","pubTime":"2025-10-19 07:13","pubTimestamp":1760829230,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) recently made headlines after presenting fresh structural and mechanistic insights for its promising drug candidate, verekitug, at a major scientific congress. This event has drawn renewed investor attention to the company.\nSee our latest analysis for Upstream Bio.\nFollowing the buzz around verekitug’s data, Upstream Bio’s share price has shown real momentum, up nearly 31% over the past month and a striking 96% in the last 90 days. But it’s worth noting the total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-fresh-data-and-analyst-coverage-spark-new-q","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/upstream-bio-upb-fresh-data-and-analyst-coverage-spark-new-q","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2575721511","title":"Upstream Bio Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2575721511","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575721511?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:19","pubTimestamp":1760447940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UPB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 14, 2025 09:19 ET (13:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2575029664","title":"Upstream Bio initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2575029664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575029664?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:15","pubTimestamp":1760436942,"startTime":"0","endTime":"0","summary":"Truist initiated coverage of Upstream Bio (UPB) with a Buy rating and $47 price target Verekitug offers similarly robust efficacy as other TSLP-rec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2574856004","title":"Why Upstream Bio (UPB) Is Up 6.5% After Positive Phase 2 Results for Verekitug in Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2574856004","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574856004?lang=en_us&edition=fundamental","pubTime":"2025-10-11 02:28","pubTimestamp":1760120883,"startTime":"0","endTime":"0","summary":"At the European Respiratory Society Congress held in Amsterdam from September 27 to October 1, 2025, Upstream Bio presented new structural and mechanistic data for verekitug, highlighting its potent pharmacodynamic activity against the TSLP receptor and positive Phase 2 results in chronic rhinosinusitis with nasal polyps.\nThis advancement, alongside updates on multiple ongoing trials in asthma and COPD, underscores the momentum of Upstream Bio’s clinical pipeline for respiratory...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/why-upstream-bio-upb-is-up-65-after-positive-phase-2-results","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/why-upstream-bio-upb-is-up-65-after-positive-phase-2-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2572535555","title":"HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572535555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572535555?lang=en_us&edition=fundamental","pubTime":"2025-10-01 23:49","pubTimestamp":1759333787,"startTime":"0","endTime":"0","summary":"Net asset value  per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs . The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs Therapeutics, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL5tnLj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","ETNB","MRUS","LU0320765992.SGD","BK4139","LU0109394709.USD","QURE","LU0889565916.HKD","BK4585","UPB"],"gpt_icon":0},{"id":"2571345035","title":"Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2571345035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571345035?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:15","pubTimestamp":1759227319,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented structural and mechanistic data showing verekitug’s potent pharmacodynamic activity through its approach of targeting ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bios-verekitug-shows-prevention-of-tslp-binding-in-respiratory-disease-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bios-verekitug-shows-prevention-of-tslp-binding-in-respiratory-disease-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB","TSLP"],"gpt_icon":0},{"id":"2571731460","title":"Upstream Bio Announces Promising Phase 2 Clinical Results for Verekitug in Severe Respiratory Diseases at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2571731460","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571731460?lang=en_us&edition=fundamental","pubTime":"2025-09-30 16:15","pubTimestamp":1759220109,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. , a clinical-stage biotechnology company focused on treatments for inflammatory diseases, has presented new data on its investigational drug verekitug at the European Respiratory Society  Congress 2025. The data highlight verekitug's unique mechanism of action, which involves targeting the thymic stromal lymphopoietin  receptor and preventing TSLP binding by occupying its ligand binding sites. Structural and mechanistic studies reveal that verekitug outcompetes TSLP even in the presence of preformed heterodimeric receptor complexes, supporting its potential for differentiated therapeutic effects in a variety of severe respiratory diseases driven by TSLP. Clinical findings from a recent Phase 2 study in chronic rhinosinusitis with nasal polyps indicate statistically significant and clinically meaningful effects with dosing every 12 weeks. Additional Phase 2 top-line data in severe asthma are expected in the first quarter of 2026. The full presentation is available on t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL2834Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","BK4588","NDAQ","UPB","IE00BKPKM429.USD","LU0314104364.USD","BK4139","IE00BGHQF748.EUR"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}